Avoro Capital Advisors’s Terns Pharmaceuticals TERN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-5,695,000
Closed -$300M 33
2026
Q1
$300M Buy
5,695,000
+1,345,000
+31% +$55.2M 2.95% 13
2025
Q4
$176M Buy
+4,350,000
New +$101M 1.73% 16

Other funds holding TERN

Avoro Capital Advisors's TERN Position: Q2 2026 in Review

Avoro Capital Advisors sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 5,695,000 shares — an estimated $300M sold.

Avoro Capital Advisors first reported a position in TERN in Q4 2025 and held it in 2 quarters. The position peaked at $300M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

  • Avoro Capital Advisors reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Avoro Capital Advisors sold 5,695,000 Terns Pharmaceuticals shares in Q2 2026, an estimated $300M.
  • Avoro Capital Advisors first reported a position in Terns Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Avoro Capital Advisors's Terns Pharmaceuticals position peaked at $300M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Avoro Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.